{"nctId":"NCT01350973","briefTitle":"Efficacy of TAK-085 in Participants With Hypertriglyceridemia","startDateStruct":{"date":"2009-11"},"conditions":["Hypertriglyceridemia"],"count":611,"armGroups":[{"label":"TAK-085 2 g","type":"EXPERIMENTAL","interventionNames":["Drug: Omega-3-acid ethyl esters 90 (TAK-085)"]},{"label":"TAK-085 4 g","type":"EXPERIMENTAL","interventionNames":["Drug: Omega-3-acid ethyl esters 90 (TAK-085)"]},{"label":"EPA-E 1.8 g","type":"EXPERIMENTAL","interventionNames":["Drug: Eicosapentaenoic acid-ethyl (EPA-E)"]}],"interventions":[{"name":"Omega-3-acid ethyl esters 90 (TAK-085)","otherNames":["LOVAZA","Omacor"]},{"name":"Eicosapentaenoic acid-ethyl (EPA-E)","otherNames":["AtheropanÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants with values of fasting triglyceride level at Visit 2 (Week -4) and Visit 3 (Week -2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference between these 2 values is within 30% of the higher one.\n2. Participants with differences between 2 values of fasting Low density lipoprotein - cholesterol level measured at Visit 2 (Week -4) and Visit 3 (Week -2) are within 25% of the higher one.\n\nExclusion Criteria:\n\n1. Participants who have coronary artery diseases (eg, confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week -8) or participants with a history of revascularization.\n2. Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm within 6 months prior to Visit 1 (Week -8).\n3. Participants who have a history or complication of a clinically significant hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within 6 months prior to Visit 1 (Week -8).\n4. Participants who have been diagnosed with pancreatitis.\n5. Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or type III familial hyperlipidemia.\n6. Participants with complication of Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Triglyceride Level at the Final Visit","description":"The percentage change between triglycerides collected at the end of study drug administration (the end of treatment period or discontinuation) relative to Baseline. Analysis of Covariance (ANCOVA) model was employed, using the Baseline triglyceride level as covariate and the treatment group as an independent variable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.93","spread":"1.6434"},{"groupId":"OG001","value":"-22.65","spread":"1.6238"},{"groupId":"OG002","value":"-11.30","spread":"1.6807"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglyceride Level Over Time","description":"The percentage change between triglycerides collected at each study visit relative to Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.085","spread":"26.4479"},{"groupId":"OG001","value":"-26.939","spread":"20.9540"},{"groupId":"OG002","value":"-11.417","spread":"27.8599"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.055","spread":"23.5955"},{"groupId":"OG001","value":"-22.501","spread":"29.7039"},{"groupId":"OG002","value":"-11.321","spread":"29.6792"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.707","spread":"25.9148"},{"groupId":"OG001","value":"-23.436","spread":"31.7008"},{"groupId":"OG002","value":"-11.416","spread":"28.4762"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.707","spread":"27.6764"},{"groupId":"OG001","value":"-22.606","spread":"25.1665"},{"groupId":"OG002","value":"-12.431","spread":"31.0903"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time","description":"The percentage change between low-density lipoprotein cholesterol collected at each study visit relative to Baseline. Low-density lipoprotein cholesterol particles measured directly by nuclear magnetic resonance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.120","spread":"16.0172"},{"groupId":"OG001","value":"2.262","spread":"15.5408"},{"groupId":"OG002","value":"-3.409","spread":"13.5003"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.846","spread":"15.5473"},{"groupId":"OG001","value":"-0.420","spread":"17.7696"},{"groupId":"OG002","value":"-3.008","spread":"13.8462"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.055","spread":"15.6128"},{"groupId":"OG001","value":"-0.862","spread":"18.0310"},{"groupId":"OG002","value":"-4.297","spread":"14.0827"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.639","spread":"16.3582"},{"groupId":"OG001","value":"-1.056","spread":"18.2732"},{"groupId":"OG002","value":"-3.393","spread":"17.2972"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol Over Time","description":"The percentage change between total cholesterol measured at each study visit relative to Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.841","spread":"10.0601"},{"groupId":"OG001","value":"-2.707","spread":"9.0969"},{"groupId":"OG002","value":"-3.152","spread":"8.1026"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.996","spread":"9.5190"},{"groupId":"OG001","value":"-2.887","spread":"9.7964"},{"groupId":"OG002","value":"-3.097","spread":"9.2770"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.054","spread":"9.0927"},{"groupId":"OG001","value":"-3.949","spread":"10.5345"},{"groupId":"OG002","value":"-4.355","spread":"9.1420"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.649","spread":"9.4133"},{"groupId":"OG001","value":"-3.243","spread":"10.6025"},{"groupId":"OG002","value":"-3.880","spread":"10.8594"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time","description":"The percentage change between high-density lipoprotein cholesterol collected at each study visit relative to Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.990","spread":"10.5365"},{"groupId":"OG001","value":"4.075","spread":"10.9735"},{"groupId":"OG002","value":"0.934","spread":"11.6203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.547","spread":"11.6333"},{"groupId":"OG001","value":"3.936","spread":"12.4198"},{"groupId":"OG002","value":"1.826","spread":"10.1747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.258","spread":"10.6907"},{"groupId":"OG001","value":"4.219","spread":"12.0895"},{"groupId":"OG002","value":"1.860","spread":"11.0573"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.685","spread":"10.8647"},{"groupId":"OG001","value":"4.564","spread":"12.7497"},{"groupId":"OG002","value":"1.741","spread":"10.8185"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time","description":"The percentage change between non-high-density lipoprotein cholesterol collected at each study visit relative to Baseline. Non-high-density lipoprotein cholesterol calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.955","spread":"12.7395"},{"groupId":"OG001","value":"-4.634","spread":"11.3386"},{"groupId":"OG002","value":"-4.274","spread":"10.8403"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.022","spread":"11.2524"},{"groupId":"OG001","value":"-4.931","spread":"11.9003"},{"groupId":"OG002","value":"-4.418","spread":"11.5415"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.624","spread":"11.2058"},{"groupId":"OG001","value":"-6.190","spread":"12.9755"},{"groupId":"OG002","value":"-5.994","spread":"11.1866"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.159","spread":"11.5205"},{"groupId":"OG001","value":"-5.384","spread":"13.2602"},{"groupId":"OG002","value":"-5.140","spread":"14.3444"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"10.81"},{"groupId":"OG001","value":"0","spread":"10.61"},{"groupId":"OG002","value":"0","spread":"10.92"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings After Study Drug Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":205},"commonTop":["Nasopharyngitis"]}}}